FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308184069> ?p ?o ?g. }

• W4308184069 endingPage "1458" @default.
• W4308184069 startingPage "1448" @default.
• W4308184069 abstract "ABSTRACT Background Whether treating metabolic acidosis slows progression of chronic kidney disease (CKD) has not been established. Veverimer is a novel hydrochloric acid binder that removes acid from the gastrointestinal tract leading to an increase in serum bicarbonate; it is being developed to treat metabolic acidosis with the goal of slowing progression of CKD. Methods The VALOR-CKD trial is an international, randomized, multicenter, double-blind, placebo-controlled study designed to evaluate the effect of once-daily veverimer on kidney disease progression in patients with metabolic acidosis and CKD. Eligibility criteria include a serum bicarbonate in the range of 12–20 mmol/L and an estimated glomerular filtration rate (eGFR) of 20–40 mL/min/1.73 m2. The primary outcome is kidney disease progression defined as the development of end-stage kidney disease, a sustained decline in eGFR of &gt;40% from baseline or death due to kidney failure. Key secondary endpoints include effects on physical function. Results Between December 2018 and December 2021, 1480 participants were randomized. The mean age at baseline was 65.1 years and 42% of the patients were female. The mean baseline eGFR was 29.1 mL/min/1.73 m2 and mean serum bicarbonate was 17.5 mmol/L. The median urine albumin-to-creatinine ratio at screening was 201 mg/g and the median 5-year predicted risk of kidney failure was 32%. Diabetes and hypertension were present in 56% and 98% of participants, respectively. Conclusions VALOR-CKD has recruited a large population of people with metabolic acidosis at high risk for CKD progression to determine the effects of veverimer on the risk of progressive loss of kidney function." @default.
• W4308184069 created "2022-11-09" @default.
• W4308184069 creator A5010386833 @default.
• W4308184069 creator A5019935894 @default.
• W4308184069 creator A5022584491 @default.
• W4308184069 creator A5027520502 @default.
• W4308184069 creator A5042762794 @default.
• W4308184069 creator A5054296834 @default.
• W4308184069 creator A5056005655 @default.
• W4308184069 creator A5058965585 @default.
• W4308184069 creator A5069865054 @default.
• W4308184069 creator A5076583644 @default.
• W4308184069 creator A5089363439 @default.
• W4308184069 creator A5091483213 @default.
• W4308184069 date "2022-11-04" @default.
• W4308184069 modified "2023-09-23" @default.
• W4308184069 title "Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis" @default.
• W4308184069 cites W1759279544 @default.
• W4308184069 cites W1994174181 @default.
• W4308184069 cites W2000366267 @default.
• W4308184069 cites W2044773944 @default.
• W4308184069 cites W2054323843 @default.
• W4308184069 cites W2056976690 @default.
• W4308184069 cites W2096568852 @default.
• W4308184069 cites W2097805169 @default.
• W4308184069 cites W2098919289 @default.
• W4308184069 cites W2108629029 @default.
• W4308184069 cites W2117650285 @default.
• W4308184069 cites W2152413054 @default.
• W4308184069 cites W2165817472 @default.
• W4308184069 cites W2761903250 @default.
• W4308184069 cites W2765955869 @default.
• W4308184069 cites W2920797532 @default.
• W4308184069 cites W2939222610 @default.
• W4308184069 cites W2950536465 @default.
• W4308184069 cites W2974750522 @default.
• W4308184069 cites W2980098671 @default.
• W4308184069 cites W2983996826 @default.
• W4308184069 cites W2994621179 @default.
• W4308184069 cites W3003235058 @default.
• W4308184069 cites W3008218273 @default.
• W4308184069 cites W3088173406 @default.
• W4308184069 cites W3092407354 @default.
• W4308184069 cites W3094429645 @default.
• W4308184069 cites W3159064206 @default.
• W4308184069 cites W3161141693 @default.
• W4308184069 cites W3165469537 @default.
• W4308184069 cites W4213426937 @default.
• W4308184069 cites W4220663642 @default.
• W4308184069 cites W4377864077 @default.
• W4308184069 cites W1991178878 @default.
• W4308184069 cites W3026731266 @default.
• W4308184069 doi "https://doi.org/10.1093/ndt/gfac289" @default.
• W4308184069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36331426" @default.
• W4308184069 hasPublicationYear "2022" @default.
• W4308184069 type Work @default.
• W4308184069 citedByCount "1" @default.
• W4308184069 countsByYear W43081840692023 @default.
• W4308184069 crossrefType "journal-article" @default.
• W4308184069 hasAuthorship W4308184069A5010386833 @default.
• W4308184069 hasAuthorship W4308184069A5019935894 @default.
• W4308184069 hasAuthorship W4308184069A5022584491 @default.
• W4308184069 hasAuthorship W4308184069A5027520502 @default.
• W4308184069 hasAuthorship W4308184069A5042762794 @default.
• W4308184069 hasAuthorship W4308184069A5054296834 @default.
• W4308184069 hasAuthorship W4308184069A5056005655 @default.
• W4308184069 hasAuthorship W4308184069A5058965585 @default.
• W4308184069 hasAuthorship W4308184069A5069865054 @default.
• W4308184069 hasAuthorship W4308184069A5076583644 @default.
• W4308184069 hasAuthorship W4308184069A5089363439 @default.
• W4308184069 hasAuthorship W4308184069A5091483213 @default.
• W4308184069 hasConcept C126322002 @default.
• W4308184069 hasConcept C134018914 @default.
• W4308184069 hasConcept C142724271 @default.
• W4308184069 hasConcept C159641895 @default.
• W4308184069 hasConcept C168563851 @default.
• W4308184069 hasConcept C203092338 @default.
• W4308184069 hasConcept C204787440 @default.
• W4308184069 hasConcept C27081682 @default.
• W4308184069 hasConcept C2775965419 @default.
• W4308184069 hasConcept C2778653478 @default.
• W4308184069 hasConcept C2779246250 @default.
• W4308184069 hasConcept C2780306776 @default.
• W4308184069 hasConcept C2908647359 @default.
• W4308184069 hasConcept C2992435398 @default.
• W4308184069 hasConcept C555293320 @default.
• W4308184069 hasConcept C71924100 @default.
• W4308184069 hasConcept C90924648 @default.
• W4308184069 hasConcept C99454951 @default.
• W4308184069 hasConceptScore W4308184069C126322002 @default.
• W4308184069 hasConceptScore W4308184069C134018914 @default.
• W4308184069 hasConceptScore W4308184069C142724271 @default.
• W4308184069 hasConceptScore W4308184069C159641895 @default.
• W4308184069 hasConceptScore W4308184069C168563851 @default.
• W4308184069 hasConceptScore W4308184069C203092338 @default.
• W4308184069 hasConceptScore W4308184069C204787440 @default.
• W4308184069 hasConceptScore W4308184069C27081682 @default.
• W4308184069 hasConceptScore W4308184069C2775965419 @default.

• next